ArriVent BioPharma, Inc. AVBP
13.01 USD -0.06 (-0.46%)
Regular-session close
13.01 0.00 0.00%
After hours · Nov 13, 4:26 PM ET
12.59 Day range 13.24
12.23 52-week range 34.74
- YTD
- -35.34%
- 1 year
- -33.89%
News
benzinga.com Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $24 Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $21 to $24.
benzinga.com ArriVent BioPharma Q3 EPS $(0.81) Beats $(1.05) Estimate, Sales $5.000M ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.05) by 22.86 percent. This is a 2.41 percent increase over losses of…
globenewswire.com ArriVent BioPharma Reports Third Quarter 2026 Financial Results Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO Dosed…
benzinga.com Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30 Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.
benzinga.com ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026 ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced…
benzinga.com B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29 B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $29.- benzinga.com BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.